Tarlatamab

Definition

A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) delta-like protein 3 (DLL3) fused to one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, tarlatamab binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and the DLL3 antigen found on DLL3-expressing tumor cells. This activates and redirects CTLs to DLL3-expressing tumor cells, which results in the CTL-mediated cell death of DLL3-expressing tumor cells. DLL3, a Notch pathway protein, is overexpressed on a variety of cancer cell types. It plays a key role in embryonic development and in tumor initiation and proliferation.

Also known as AMG 757, AMG-757, AMG757, Anti-DLL3 x Anti-CD3 BiTE AMG 757, Bispecific T-cell Engager Antibody AMG 757, BiTE Antibody AMG 757, DLL3/CD3-directed Bispecific T-cell Engager Antibody AMG 757, Imdelltra, TARLATAMAB, Tarlatamab-dlle — per NCIT

Also identified as

• ATC L01FX33 per RXNORM
• NCIT NCIT:C175858 per NCIT
• SCTID 92911000087102 per RXNORM
• UNII 74X82ST8Q1 per RXNORM

Indications